Meanwhile, rhPD-1 treatment also increased TGFβ production in NSCLC cells (Fig. 3h), and anti-TGFβ neutralizing antibody restored the EMT phenotype promoted by rhPD-1 treatment (Fig. 3i and Supplementary Fig. S3F). Here, NPHP3 is linked to non-small cell lung carcinoma.